Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 49

Sort by

Sort Order Select

Journal Articles

How I treat primary ITP in adult patients who are unresponsive to or dependent on corticosteroid treatment

Waleed Ghanima, Terry Gernsheimer, David J. Kuter

Blood (2021) 137 (20): 2736–2744.

https://doi.org/10.1182/blood.2021010968

Published: 2021

Journal Articles

Real-World Experience with Fostamatinib in Patients with Immune Thrombocytopenia at an Academic Medical Center

David Hughes, PharmD, Frances Blevins, PA-C, Bhavesh Shah, RPh, Shayna Sarosiek, Adam Lerner, MD, John Mark Sloan, MD

Blood (2019) 134 (Supplement_1): 4912.

https://doi.org/10.1182/blood-2019-124740

Published: 2019

Journal Articles

Trial in Progress: Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Global Study of Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

Nichola Cooper, MD MRCP, Isabel Gorham, BS RN, Ann M. Lowe, MD, Robert P. Numerof, PhD, Sandy Tong, MD, David J. Kuter

Blood (2019) 134 (Supplement_1): 4800.

https://doi.org/10.1182/blood-2019-126544

Published: 2019

Journal Articles

Evaluation of the Oral SYK Inhibitor Fostamatinib in Patients after Allogeneic Transplantation for Chronic Graft-Versus-Host Disease

William C. McManigle, MD, Rachel A. DiCioccio, BS, Sarah Anand, MD, Zhiguo Li, PhD, Jonathan C Poe, PhD, Krista R. Nichols, RN, MSN, AOCNS, Amy N. Suthers, PhD, Wei Jia, MD PhD, Kelly Corbet, BS, Megan Covington, BS, Julia Lloyd-Cowden, BS, Richard D. Lopez, MD, Gwynn D. Long, MD, Mitchell E. Horwitz, MD, Cristina Gasparetto, MD, Anthony D. Sung, MD, Nelson J. Chao, MD, David A. Rizzieri, MD, Stefanie Sarantopoulos, MD PhD

Blood (2019) 134 (Supplement_1): 4521.

https://doi.org/10.1182/blood-2019-130742

Published: 2019

Journal Articles

Tyrosine Kinase Inhibitors (TKIs) Targeting Syk and BTK Signaling Differentially Affect PI3K Signalosome Organization and Platelet Function

Tony Zheng, Elizabeth R Lofurno, Sarah Elgamal, Alexander R Melrose, Jiaqing Pang, Joseph J Shatzel, MD, Owen J T McCarty, PhD, Joseph Aslan, PhD

Blood (2019) 134 (Supplement_1): 2074.

https://doi.org/10.1182/blood-2019-129066

Published: 2019

Journal Articles

A Systematic Review and Meta-Analysis of Cardio-Vascular Side Effects with Fostamatinib a Spleen Tyrosine Kinase Inhibitor

Muhammad Zain Farooq, MD MBBS, Prasanth Lingamaneni, Saira Farid, MD, Muhammad Saad Farooq, MBBS, Ishaan Vohra, MD, Asim Tameez ud din, MD, Ankit Mangla, MBBS,MD

Blood (2019) 134 (Supplement_1): 3465.

https://doi.org/10.1182/blood-2019-132151

Published: 2019

Journal Articles

Fostamatinib, a Spleen Tyrosine Kinase (SYK) Inhibitor, for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (wAIHA): Final Results of the Phase 2, Multicenter, Open-Label Study

Kerry A. Rogers, MD, Michael A. Boxer, MD, Michael Y. Choi, MD, Richy Agajanian, MD, Donald M. Arnold, MD, Catherine M. Broome, MD, Joshua J. Field, MD, Irina Murakhovskaya, MD, Donna Chow, Robert P. Numerof, PhD, Hanzhe Zheng, PhD, Sandy Tong, MD, David J. Kuter

Blood (2019) 134 (Supplement_1): 3518.

https://doi.org/10.1182/blood-2019-126509

Published: 2019

Journal Articles

Safety Profile of Fostamatinib, an Oral Spleen Tyrosine Kinase Inhibitor: A Meta-Analysis of Randomized Controlled Trials

Apoorva Krishna Chandar, MDMPH, Omar Ali Alaber, MD, Muhammad Zain Farooq, MD MBBS, Basma Ali Dahash, MD, Ankit Mangla, MBBS, MD

Blood (2019) 134 (Supplement_1): 4890.

https://doi.org/10.1182/blood-2019-127782

Published: 2019

Journal Articles

Potential Anti-Thrombotic Effect without Accompanying Hemorrhage with Fostamatinib Use in Patients with Immune Thrombocytopenia

Ivy Altomare, MD, Vadim V. Markovtsov, PhD, Leslie Todd, Dheepika Weerasinghe, PhD, Robert P. Numerof, PhD, Sandy Tong, MD, Esteban Masuda, PhD, James B. Bussel, MD

Blood (2019) 134 (Supplement_1): 4889.

https://doi.org/10.1182/blood-2019-126558

Published: 2019

Journal Articles

Enhanced Responses to Fostamatinib As Second-Line Therapy and in Persistent Immune Thrombocytopenia (ITP) Patients

Ralph Boccia, MD, Michael A. Boxer, MD, Waleed Ghanima, MD PhD, Quentin A. Hill, Michelle Sholzberg, MDBSc,FRCPC,MSc, Michael D. Tarantino, MD, Yuliya Kreychman, PharmD, Robert P. Numerof, PhD, Brian Olender, BA, Leslie Todd, Sandy Tong, MD, Anne-Marie Duliege, MDMS, Nichola Cooper, MD MRCP, James B. Bussel, MD

Blood (2019) 134 (Supplement_1): 1069.

https://doi.org/10.1182/blood-2019-126473

Published: 2019

Journal Articles

Long Term Remission Achieved By Fostamatinib in ITP: A Case Report

Waleed Ghanima, MD PhD, Tjønnfjord Eirik, MD PhD

Blood (2019) 134 (Supplement_1): 4901.

https://doi.org/10.1182/blood-2019-128359

Published: 2019

Journal Articles

Fostamatinib for the treatment of chronic immune thrombocytopenia

Nathan T. Connell, Nancy Berliner

Blood (2019) 133 (19): 2027–2030.

https://doi.org/10.1182/blood-2018-11-852491

Published: 2019

Journal Articles

Two-Year Safety and Efficacy Outcomes with Fostamatinib in Adult Patients with Immune Thrombocytopenia (ITP): Open-Label Extension to Phase 3 Trial Program

Anne-Marie Duliege, MDMS, Donald M. Arnold, MD MSc, FRCPC, Ralph Boccia, MD, Michael Boxer, MD, Nichola Cooper, MRCP, Quentin A Hill, BSc, MBChB, MRCP, FRCPath, Darla K Liles, MD, Michelle Sholzberg, MDM, MSc, FRCPC, Hany Zayed, PhD, Sandra Tong, MD, James B. Bussel, MD

Blood (2018) 132 (Supplement 1): 736.

https://doi.org/10.1182/blood-2018-99-110482

Published: 2018

Journal Articles

Prediction of Response to Fostamatinib Based on the Presence of Plasma Platelet Autoantibodies in Adult Patients with Immune Thrombocytopenia (ITP) — Exploratory Analyses from Phase 3 Studies

Vadim V. Markovtsov, PhD, Sothy Yi, Chi Young, Anne-Marie Duliege, MD MS, Esteban Masuda, PhD

Blood (2018) 132 (Supplement 1): 3766.

https://doi.org/10.1182/blood-2018-99-113705

Published: 2018

Journal Articles

Expanding the Utility of Midostaurin in Acute Myeloid Leukemia - Predictive Mutational Signatures in Patient Samples without FLT3 mutations and Clinically Applicable Synergistic Drug Combinations

Markus Vaha-Koskela, PhD, Muhammad Ammad-ud-din, PhD, Kirsi Siivola, MSc, Tanja Ruokoranta, MSc, Laura Turunen, PhD, Kimmo Porkka, MD PhD, Pedro Marques Ramos, PhD, Celine Pallaud, PhD, Tero Aittokallio, PhD, Krister Wennerberg, PhD

Blood (2018) 132 (Supplement 1): 2743.

https://doi.org/10.1182/blood-2018-99-116391

Published: 2018

Journal Articles

Fostamatinib, a Spleen Tyrosine Kinase Inhibitor, for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia: Initial Results of the Multicenter, Open-Label Extension Period of the Soar Phase 2 Study

David J. Kuter, MD DPhil, Richy Agajanian, MD, Donald M. Arnold, MD MSc, FRCPC, Michael Boxer, MD, Catherine Broome, MD, Joshua J. Field, MD, Irina Murakhovskaya, MD, Kerry A. Rogers, MD, Ann M Lowe, MD, Sandra Tong, MD, Hany Zayed, PhD, Anne-Marie Duliege, MD MS

Blood (2018) 132 (Supplement 1): 3612.

https://doi.org/10.1182/blood-2018-99-110483

Published: 2018

Journal Articles

SHP1 Deficiency Is Responsible for the Constitutive Activation of the BCR Pathway in GCB DLBCL

Binu K Sasi, PhD, Sven Turkalj, BS, Hilal Kalkan, BS, Fabiola Porro, MS, Engin Bojnik, PhD, Beata Pyrzynska, PhD, Abdessamad Zerrouqi, PhD, Malgorzata Bobrowicz, PhD, Magdalena Winiarska, PhD, Valdemar Priebe, MS, Francesco Bertoni, MD, Larry Mansouri, PhD, Richard Rosenquist, MD PhD, Dimitar G Efremov, MD PhD

Blood (2018) 132 (Supplement 1): 2860.

https://doi.org/10.1182/blood-2018-99-118120

Published: 2018

Journal Articles

A Case Report of Refractory Immune Thrombocytopenia (ITP) Following Reduced Intensity Conditioning (RIC) Hematopoietic Cell Transplantation (HCT) for Myelodysplastic Syndrome (MDS) Successfully Treated with Off-Label Use of Daratumumab

Yazan Migdady, MD MSc, Ridhi Gupta, MBBS, Asiri Ediriwickrema, MD, Francisco Socola, MD, Sally Arai, MD, Beth A Martin, MD

Blood (2018) 132 (Supplement 1): 4976.

https://doi.org/10.1182/blood-2018-99-116560

Published: 2018

Journal Articles

Using Informatics Tools to Characterize Precision Medicine Treatments for Diffuse Large B-Cell Lymphoma (DLBCL)

Sharvil Piyush Patel, Andrew Harkins, Michelle J Lee, PhD, Christopher R Flowers

Blood (2018) 132 (Supplement 1): 4801.

https://doi.org/10.1182/blood-2018-99-119917

Published: 2018

Journal Articles

Regulation and Impact of BCR Induced Autophagy in Chronic Lymphocytic Leukemia

Lindsay D Smith, PhD, Laura I Karydis, PhD, Margaret Ashton-Key, MD, Jonathan C Strefford, PhD, Freda K. Stevenson, DPhil, Graham Packham, PhD, Mark Cragg, PhD, David A Tumbarello, PhD, Matthew D Blunt, PhD, Francesco Forconi, MD DM, PhD FRCPath, Andrew J Steele, PhD

Blood (2017) 130 (Supplement 1): 1717.

https://doi.org/10.1182/blood.V130.Suppl_1.1717.1717

Published: 2017

NARROW

How I treat primary ITP in adult patients who are unresponsive to or dependent on corticosteroid treatment

Real-World Experience with Fostamatinib in Patients with Immune Thrombocytopenia at an Academic Medical Center

Trial in Progress: Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Global Study of Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

Evaluation of the Oral SYK Inhibitor Fostamatinib in Patients after Allogeneic Transplantation for Chronic Graft-Versus-Host Disease

Tyrosine Kinase Inhibitors (TKIs) Targeting Syk and BTK Signaling Differentially Affect PI3K Signalosome Organization and Platelet Function

A Systematic Review and Meta-Analysis of Cardio-Vascular Side Effects with Fostamatinib a Spleen Tyrosine Kinase Inhibitor

Fostamatinib, a Spleen Tyrosine Kinase (SYK) Inhibitor, for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (wAIHA): Final Results of the Phase 2, Multicenter, Open-Label Study

Safety Profile of Fostamatinib, an Oral Spleen Tyrosine Kinase Inhibitor: A Meta-Analysis of Randomized Controlled Trials

Potential Anti-Thrombotic Effect without Accompanying Hemorrhage with Fostamatinib Use in Patients with Immune Thrombocytopenia

Enhanced Responses to Fostamatinib As Second-Line Therapy and in Persistent Immune Thrombocytopenia (ITP) Patients

Long Term Remission Achieved By Fostamatinib in ITP: A Case Report

Fostamatinib for the treatment of chronic immune thrombocytopenia

Two-Year Safety and Efficacy Outcomes with Fostamatinib in Adult Patients with Immune Thrombocytopenia (ITP): Open-Label Extension to Phase 3 Trial Program

Prediction of Response to Fostamatinib Based on the Presence of Plasma Platelet Autoantibodies in Adult Patients with Immune Thrombocytopenia (ITP) — Exploratory Analyses from Phase 3 Studies

Expanding the Utility of Midostaurin in Acute Myeloid Leukemia - Predictive Mutational Signatures in Patient Samples without FLT3 mutations and Clinically Applicable Synergistic Drug Combinations

Fostamatinib, a Spleen Tyrosine Kinase Inhibitor, for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia: Initial Results of the Multicenter, Open-Label Extension Period of the Soar Phase 2 Study

SHP1 Deficiency Is Responsible for the Constitutive Activation of the BCR Pathway in GCB DLBCL

A Case Report of Refractory Immune Thrombocytopenia (ITP) Following Reduced Intensity Conditioning (RIC) Hematopoietic Cell Transplantation (HCT) for Myelodysplastic Syndrome (MDS) Successfully Treated with Off-Label Use of Daratumumab

Using Informatics Tools to Characterize Precision Medicine Treatments for Diffuse Large B-Cell Lymphoma (DLBCL)

Regulation and Impact of BCR Induced Autophagy in Chronic Lymphocytic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only